Sino Biopharmaceutical Limited (OTCMKTS:SBMFF) Short Interest Down 100.0% in June

Sino Biopharmaceutical Limited (OTCMKTS:SBMFF) saw a significant decline in short interest in June. As of June 15th, there was short interest totalling 13,900 shares, a decline of 100.0% from the May 31st total of 41,764,200 shares. Based on an average trading volume of 1,100 shares, the short-interest ratio is presently 12.6 days.

Sino Biopharmaceutical Stock Performance

SBMFF stock traded down $0.02 during trading hours on Thursday, hitting $0.31. The company’s stock had a trading volume of 3,447 shares, compared to its average volume of 307. The stock has a 50 day moving average price of $0.33 and a two-hundred day moving average price of $0.36. Sino Biopharmaceutical has a 12 month low of $0.31 and a 12 month high of $0.49.

About Sino Biopharmaceutical

Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People's Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The company offers oncology medicines, including anlotinib hydrochloride capsules under Focus V brand, penpulimab injection under Annike brand, efbemalenograstin alfa injection under Yilishu brand, pomalidomide capsules under Anyue brand, bevacizumab injection under Anbeisi brand, rituximab injection under Delituo brand, and trastuzumab for injection under Saituo brand; liver disease medications, such as magnesium isoglycyrrhizinate injection under Tianqing Ganmei brand and entecavir dispersible tablets under Runzhong brand; and respiratory system medicines comprising budesonide suspension for inhalation under Tianqing suchang brand and colistimethate sodium for injection under Tianyun brand.